February 2026—Illumina announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services will expand access to comprehensive genomic profiling. TSO Comprehensive is reimbursed under the clinical laboratory fee schedule effective Jan. 1 at a rate of $2,989.55 using proprietary laboratory analyses code 0543U.
Illumina, 858-202-4500